SAN DIEGO, March 27 /PRNewswire/ -- Studies reported in March 23’s Proceeding of the National Academy of Sciences by Dr Xiandong Fu’s laboratory at the University of California, San Diego (UCSD) and Aviva Systems Biology (ASB) demonstrated the super-sensitivity of ASB’s core ChIP-DSL (Chromatin Immunoprecipitation-DNA Selection and Ligation) technology for its Biomarker discovery application. Utilizing ChIP-DSL’s ability to detect virtually all DNA-protein interactions with limited cancer cell sample (106cells), researchers identified a set of 54 potential prognostic human breast cancer biomarkers that correlate to the predicted outcome of Estrogen Receptor (ER) treatment for breast cancer patients. These studies also detected far more ER interactive promoters throughout the genome than was previously observed, illustrating ChIP-DLS’s power of sensitivity and specificity.
“The identification of these potential breast cancer biomarkers demonstrates the power of the ChIP-DSL technology in identifying disease related biomarkers that may have significant therapeutic and diagnostic applications” stated ASB CEO, Julian Yuan, “and serves as a milestone for applying ChIP-DSL to biomarker discovery in the pharmaceutical industry.”
Based in San Diego, California, ASB is dedicated to the development of reagents for transcription factor research including antibodies to all putative transcription factors. ASB also generates antibodies and additional reagents for other important research areas.
Contact: To learn more about ASB or ChIP-DSL, email Jeff Falk, Ph.D, Director of Technology Applications, jfalk@avivasysbio.com, +1-858-552-6979.
Web Site: http://www.avivasysbio.com
Aviva Systems Biology
CONTACT: Jeff Falk, Ph.D, Director of Technology Applications of AvivaSystems Biology, +1-858-552-6979, jfalk@avivasysbio.com
Web site: http://www.avivasysbio.com/
